Mind-NRG, a CNS Focused Company
Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain.
NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.
About Central Nervous System (CNS) Growth Factors
Neurodegeneration could be defined as the irreversible loss of neuronal properties, either because the cells dye, or because they are not able anymore of generating new connections, or strengthening and maintaining the old ones. CNS growth factors are involved in the development of the brain and in the adulthood they are responsible for normal neuronal functioning. The excitement behind CNS growth factors is that not only could they be protective, but there is the possibility for regenerating or rejuvenating some of the sick cells in the brain.
An increasingly important amount of evidences in animal studies and initial trials in humans show that CNS growth factors can slow or even reverse the neuronal death that incapacitates patients with Parkinson or Alzheimer's disease. Neurotrophic factors injected in the brain of parkinsonian patients promoted neuronal fibers' sprouting at the administration site. In other experiments the patients have shown a clear improvement in movement and motor skills, confirming previous reports in non-human primates.
However delivery of these big molecules into the brain through the blood brain barrier is a tremendous hurdle and intracranial injections are not a therapeutic option.
NRG-101 belongs to the complex family of Neuregulins. Neuregulins are CNS growth factors involved in illness-relevant neural processes, including neuronal migration, axonal guidance, synaptic plasticity and glutamatergic dendritic spine maturation. Preliminary experiments in relevant pre-clinical models of neurodegeneration show unprecedented results for NRG-101 in cognition improvement and restoration of the neural architecture.
Unlike the other CNS growth factor in development NRG-101 has the property to cross the blood brain barrier by a receptor-mediated transport. Thanks to this unique product feature, NRG-101 can be administered via intravenous or subcutaneous injection which opens the door to its development as a new and viable therapeutic option for patients suffering from severely debilitating diseases.
For more detailed information about NRG-101 potential, please take a look to the selected literature.^ Back to top